Quantitative Concept
AbbVie Raises 2025 Guidance and Eyes Strategic Deals in Neuroscience, Obesity, and Oncology
AbbVie; 2025 guidance; earnings; neuroscience; obesity; PD-1/VEGF; strategic deals; pharmaceuticals
Moderna to Cut 10% of Workforce in $1.5B Cost-Saving Push
Moderna; layoffs; workforce reduction; cost-cutting; $1.5 billion savings; 2025; Stéphane Bancel; biotechnology; COVID-19 vaccine
Lilly’s Mounjaro Matches Cardiovascular Benefit of Trulicity in Landmark Trial, Paving Way for Expanded Approval
Mounjaro; tirzepatide; Eli Lilly; cardiovascular outcomes; type 2 diabetes; SURPASS-CVOT; Trulicity; dulaglutide; major adverse cardiovascular events (MACE-3); non-inferiority; A1C reduction; weight loss; mortality; FDA expansion
Clinical Roundup: Cardiff, VYNE and NewAmsterdam Report Key Trial Results in Multiple Disease Areas
Cardiff Oncology; VYNE; NewAmsterdam Pharma; clinical trial updates; onvansertib; metastatic colorectal cancer; Alzheimer’s disease; BROADWAY trial; oncology; statistically significant results
Teva Execs Shrug Off Pharmaceutical Tariff Threat as Turnaround Strategy Rolls Forward
Teva; tariff threat; pharmaceutical tariffs; turnaround strategy; supply chain; pivot to growth; earnings; innovative medicines; Richard Francis; operating profit margin
Jaypirca Demonstrates Superior Efficacy Over Imbruvica in BTK Inhibitor Clash for CLL/SLL
Jaypirca; Imbruvica; BTK inhibitor; chronic lymphocytic leukemia; small lymphocytic lymphoma; BRUIN CLL-314; overall response rate; progression-free survival; head-to-head trial; Eli Lilly
Merck Terminates Midstage Asset from $1.9B Pandion Acquisition over Lack of Clinical Benefit
Merck; Pandion Therapeutics; asset termination; clinical trial; lack of benefit; biotech acquisition
Merck & Co. Targets $3B in Cost Savings Through Restructuring, Including Job Cuts
Merck & Co.; cost-cutting; $3 billion savings; restructuring; job cuts; 2027 target; restructuring charges; R&D; manufacturing investments
Merck Announces $3 Billion Cost-Cutting and Restructuring Plan
Merck; cost cutting; restructuring; job cuts; real estate reduction; Keytruda; pharmaceutical industry; Q2 2025 financials
Rocket Pharmaceuticals Cuts 30% of Staff, Refocuses on Heart Gene Therapies
Rocket Pharmaceuticals; layoffs; restructuring; 30% workforce reduction; cardiovascular gene therapy; adeno-associated virus (AAV); Danon disease; PKP2-associated cardiomyopathy; BAG3-associated dilated cardiomyopathy; operating cost reduction; Fanconi Anemia; Pyruvate Kinase Deficiency; KRESLADI